keyword
Keywords Gastroenteropancreatic neuroen...

Gastroenteropancreatic neuroendocrine tumor

https://read.qxmd.com/read/38534501/improving-generalizability-of-pet-dl-algorithms-list-mode-reconstructions-improve-dotatate-pet-hepatic-lesion-detection-performance
#1
JOURNAL ARTICLE
Xinyi Yang, Michael Silosky, Jonathan Wehrend, Daniel V Litwiller, Muthiah Nachiappan, Scott D Metzler, Debashis Ghosh, Fuyong Xing, Bennett B Chin
Deep learning (DL) algorithms used for DOTATATE PET lesion detection typically require large, well-annotated training datasets. These are difficult to obtain due to low incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and the high cost of manual annotation. Furthermore, networks trained and tested with data acquired from site specific PET/CT instrumentation, acquisition and processing protocols have reduced performance when tested with offsite data. This lack of generalizability requires even larger, more diverse training datasets...
February 27, 2024: Bioengineering
https://read.qxmd.com/read/38524630/expression-and-clinical-value-of-cxcr4-in-high-grade-gastroenteropancreatic-neuroendocrine-neoplasms
#2
JOURNAL ARTICLE
Chaoyu Pang, Yongzheng Li, Ming Shi, Zhiyao Fan, Xin Gao, Yufan Meng, Shujie Liu, Changhao Gao, Peng Su, Xiao Wang, Hanxiang Zhan
BACKGROUND: CXC chemokine receptor 4 (CXCR4) is associated with the progression and metastasis of numerous malignant tumors. However, its relationship with Gastroenteropancreatic Neuroendocrine Neoplasms Grade 3 (GEP-NENs G3) is unclear. The aim of this study was to characterize the expression of CXCR4 in GEP-NENS and to explore the clinical and prognostic value of CXCR4. METHODS: This study retrospectively collected clinical and pathological data from patients with GEP-NENs who receiving surgery in Qilu Hospital of Shandong University from January 2013 to April 2021, and obtained the overall survival of the patients based on follow-up...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38498693/177lu-dotatate-salvage-therapy-in-rapidly-progressing-neuroendocrine-tumor-with-poor-performance-status
#3
JOURNAL ARTICLE
Piyush Aggarwal, Ajay Kumar, Ashwani Sood, Rama Walia, Sanjay Kumar Bhadada, Bhagwant Rai Mittal
Peptide receptor radionuclide therapy (PRRT) has shown to be effective and safe in metastatic gastroenteropancreatic and nongastroenteropancreatic neuroendocrine tumors. However, the selection criteria for PRRT are restricted to patients with good performance status (Eastern Cooperative Oncology Group score ≤2 or Karnofsky performance score ≥60). This denies many patients with adequate somatostatin receptor expression and biochemical profiles from the beneficial effects of PRRT on the quality of life, daily function, and overall survival...
March 18, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38486421/retrospective-analyses-of-pd-l1-lag-3-tim-3-ox40l-expressions-and-msi-status-in-gastroenteropancreatic-neuroendocrine-neoplasms
#4
JOURNAL ARTICLE
Fatih Gürler, Selin Aktürk Esen, Bediz Kurt İnci, Osman Sütçüoğlu, Gökhan Uçar, Orhun Akdoğan, Doğan Uncu, Nesrin Turhan, Nalan Akyürek, Nuriye Özdemir, Ahmet Özet, Ozan Yazıcı
We investigated expressions of PD-L1, LAG-3, TIM-3, and OX40L as immune checkpoint proteins, and MSI (repetitive short-DNA-sequences due to defective DNA-repair system) status were analyzed with immunohistochemistry from tissue blocks. Of 83 patients, PD-L1 expression was observed in 18.1% (n = 15) of the patients. None of the patients exhibited LAG-3 expression. TIM-3 expression was 4.9% (n = 4), OX40L was 22.9% (n = 19), and 8.4% (n = 7) of the patients had MSI tumor...
March 14, 2024: Cancer Investigation
https://read.qxmd.com/read/38485273/efficacy-of-67-cu-cu-eb-tate-theranostic-against-somatostatin-receptor-subtype-2-positive-neuroendocrine-tumors
#5
JOURNAL ARTICLE
Fabrice Ngoh Njotu, Jessica Pougoue Ketchemen, Anjong Florence Tikum, Hanan Babeker, Brian D Gray, Koon Y Pak, Maruti Uppalapati, Humphrey Fonge
β- -emitting 177 Lu-octreotate is an approved somatostatin receptor subtype 2 (SSTR2)-directed peptide receptor radionuclide therapy for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). However,177 Lu-octreotate has fast pharmacokinetics, requiring up to 4 treatment doses. Moreover, 177 Lu is less than ideal for theranostics because of the low branching ratio of its γ-emissions, which limits its SPECT imaging capability. Compared with 177 Lu, 67 Cu has better decay properties for use as a theranostic...
March 14, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38449852/risk-factors-prognostic-factors-and-nomograms-for-distant-metastases-in-patients-with-gastroenteropancreatic-neuroendocrine-tumors-a-population-based-study
#6
JOURNAL ARTICLE
Xinwei Li, Yongfei Fan, Jichun Tong, Ming Lou
BACKGROUND: Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a poor prognosis for distant metastasis. Currently, there are no studies on predictive models for the risk of distant metastasis in GEP-NETs. METHODS: In this study, risk factors associated with metastasis in patients with GEP-NETs in the Surveillance, Epidemiology, and End Results (SEER) database were analyzed by univariate and multivariate logistic regression, and a nomogram model for metastasis risk prediction was constructed...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38438338/an-illustrated-review-of-the-recent-2019-world-health-organization-classification-of-neuroendocrine-neoplasms-a-radiologic-and-pathologic-correlation
#7
JOURNAL ARTICLE
Stephan Ursprung, Lisa Zhang, Luigi Asmundo, Mina Hesami, Zhara Najmi, Lina Garcia Cañamaque, Anuradha S Shenoy-Bhangle, Theodore T Pierce, Amirkasra Mojtahed, Michael A Blake, Rory Cochran, Konstantin Nikolau, Mukesh G Harisinghani, Onofrio A Catalano
Recent advances in molecular pathology and an improved understanding of the etiology of neuroendocrine neoplasms (NENs) have given rise to an updated World Health Organization classification. Since gastroenteropancreatic NENs (GEP-NENs) are the most common forms of NENs and their incidence has been increasing constantly, they will be the focus of our attention. Here, we review the findings at the foundation of the new classification system, discuss how it impacts imaging research and radiological practice, and illustrate typical and atypical imaging and pathological findings...
February 27, 2024: Journal of Computer Assisted Tomography
https://read.qxmd.com/read/38427960/neoadjuvant-peptide-receptor-radionuclide-therapy-in-a-rare-case-of-pediatric-primary-hepatic-gastrinoma
#8
JOURNAL ARTICLE
Sougata Mahato, Piyush Aggarwal, Chennakeshava Thunga, Ashwani Sood, Ravi P Kanojia, Ritambhra Nada, Sadhna B Lal
Gastrinomas with predilection for the adult male population are located in the gastrinoma triangle (>90%). Primary hepatic gastrinoma especially in pediatric population is very rare. Peptide receptor radionuclide therapy has shown benefit in metastatic gastroenteropancreatic neuroendocrine tumors (NETs) with an increasing interest in expanding its role as neoadjuvant treatment modality to improve the surgical candidature in inoperable NETs. There is currently no literature supporting its role in the pediatric NET patients...
April 1, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38422348/efficacy-and-safety-of-streptozocin-based-chemotherapy-for-gastroenteropancreatic-neuroendocrine-tumors-in-japanese-clinical-practice
#9
JOURNAL ARTICLE
Masatoshi Murakami, Nao Fujimori, Yu Takamatsu, Tetsuhide Ito, Kazuhide Matsumoto, Shotaro Kakehashi, Akihisa Ohno, Katsuhito Teramatsu, Keijiro Ueda, Kousei Ishigami, Yoshihiro Ogawa
BACKGROUND: Streptozocin has been used to treat neuroendocrine tumors in Europe and the USA; however, its actual status in Japan has not been fully clarified owing to the rarity of this disease and the relatively recent approval of streptozocin in Japan. METHODS: We retrospectively analyzed 53 patients with gastroenteropancreatic neuroendocrine tumors who were treated with streptozocin-based chemotherapy at two Japanese hospitals between January 2004 and June 2023...
February 29, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38392065/virtual-care-for-patients-with-advanced-well-differentiated-gastroenteropancreatic-neuroendocrine-tumor-gep-net
#10
JOURNAL ARTICLE
William J Phillips, Michelle Pradier, Rachel Goodwin, Michael Vickers, Tim Asmis
INTRODUCTION: The COVID-19 pandemic resulted in an unprecedent shift towards virtual cancer care, including the care of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The aim of this study was to evaluate the use of virtual care for GEP-NETs during the COVID-19 pandemic at a high-volume academic cancer center. METHODS: This retrospective, observational study performed at the Ottawa Hospital Cancer Center in Canada evaluated adult patients with GEP-NETs seen in consultation by medical oncology between 1 June 2019 and 31 December 2022...
February 8, 2024: Current Oncology
https://read.qxmd.com/read/38374188/somatostatin-receptor-2-sstr2-expression-is-associated-with-better-clinical-outcome-and-prognosis-in-rectal-neuroendocrine-tumors
#11
JOURNAL ARTICLE
Joo Young Kim, Jisup Kim, Yong-Il Kim, Dong-Hoon Yang, Changhoon Yoo, In Ja Park, Baek-Yeol Ryoo, Jin-Sook Ryu, Seung-Mo Hong
Somatostatin analogues have recently been used as therapeutic targets for metastatic or surgically unresectable gastroenteropancreatic (GEP) neuroendocrine tumors (NETs), and associated somatostatin receptor (SSTR) expression has been well demonstrated in most GEP NETs, with the exception of rectal NETs. SSTR2 immunohistochemical expressions were evaluated in 350 surgically or endoscopically resected rectal NETs and compared to clinicopathologic factors. SSTR2 expression was observed in 234 (66.9%) rectal NET cases and associated tumors with smaller size (p = 0...
February 19, 2024: Scientific Reports
https://read.qxmd.com/read/38311997/-plasma-mirna-expression-in-patients-with-genetically-confirmed-multiple-endocrine-neoplasia-type-1-syndrome-and-its-phenocopies
#12
JOURNAL ARTICLE
D A Trukhina, E O Mamedova, A G Nikitin, P A Koshkin, Zh E Belaya, G A Melnichenko
BACKGROUND: MEN-1 is a rare autosomal dominant disease caused by mutations in MEN1 gene encoding the menin protein. This syndrome is characterized by the occurrence of parathyroid tumors, gastroenteropancreatic neuroendocrine tumors, pituitary adenomas, as well as other endocrine and non-endocrine tumors. If a patient with the MEN-1 phenotype carry no mutations in the MEN1 gene, the condition considers a phenocopy of syndrome (phMEN1). The possible cause of this changes could be changes in epigenetic regulation, particularly in microRNA expression that might affect menin signaling pathways...
January 24, 2024: Problemy E̊ndokrinologii
https://read.qxmd.com/read/38275868/radiation-exposure-from-gep-net-surveillance
#13
JOURNAL ARTICLE
Jordan Iannuzzi, Caitlin T Yeo, Vicky Parkins, Dean Ruether, Errol Stewart, Denise Chan, Janice Pasieka, Kirstie Lithgow
BACKGROUND: Neuroendocrine tumors (NET) are neoplasms that secrete peptides and neuroamines. For gastroenteropancreatic (GEP) NET, surgical resection represents the only curative option. Ten-year imaging surveillance programs are recommended due to long time-to-recurrence following resection. We performed retrospective chart review evaluating radiation exposure and practice patterns from surveillance of completely resected GEP NET. METHODS: We performed a retrospective cohort study of cases with well-differentiated GEP NET from January 2005 to July 2020...
January 19, 2024: Cancers
https://read.qxmd.com/read/38271237/radiosensitizing-favors-response-to-peptide-receptor-radionuclide-therapy-in-patients-with-highly-proliferative-neuroendocrine-malignancies-preliminary-evidence-from-a-clinical-pilot-study
#14
JOURNAL ARTICLE
Nils Florian Trautwein, Clemens Hinterleitner, Lena Sophie Kiefer, Stephan Singer, Sven Mattern, Johannes Schwenck, Gerald Reischl, Bence Sipos, Ulrich M Lauer, Helmut Dittmann, Lars Zender, Christian la Fougère, Martina Hinterleitner
AIM/INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) represents a cornerstone of treatment regimens for patients with low proliferative neuroendocrine tumors (NETs). However, in patients experiencing somatostatin receptor-positive NET with higher proliferation rates, a value and potential therapeutic benefit of PRRT as part of multimodal treatment approaches and potentially with addition of radiosensitizing agents has not yet been established. PATIENTS AND METHODS: In this study, 20 patients with histologically confirmed gastroenteropancreatic (GEP) NET with proliferation rates (Ki67) between 15% and 55% were treated either with PRRT only (n = 10) or with a combination therapy (n = 10) comprising PRRT and capecitabine/temozolomide (CAP/TEM) for at least 2 consecutive cycles...
January 23, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38252861/peptide-receptor-radionuclide-therapy-using-177lu-dotatate-nursing-roles-in-managing-patients-with-gastroenteropancreatic-neuroendocrine-tumors
#15
REVIEW
Bonita Bennett, Linda Gardner, Pamela Ryan
BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a diverse family of cancers that occur within the gastrointestinal tract and pancreas. Peptide receptor radionuclide therapy (PRRT) via 177Lu-DOTATATE is a newer therapeutic option for certain patients with somatostatin receptor-positive GEP-NETs. OBJECTIVES: This review informs on how oncology nurses treating patients with GEP-NETs receiving PRRT using 177Lu-DOTATATE can facilitate care. METHODS: Guidance on the monitoring, management, and care of patients undergoing PRRT for GEP-NETs was developed based on published literature and the nursing experience of the authors...
January 18, 2024: Clinical Journal of Oncology Nursing
https://read.qxmd.com/read/38241384/combined-the-surgery-radiation-and-chemotherapy-for-predicting-overall-survival-in-patients-with-gastroenteropancreatic-neuroendocrine-tumors
#16
JOURNAL ARTICLE
Zenghong Wu, Guochen Shang, Kun Zhang, Weijun Wang, Mengke Fan, Rong Lin
BACKGROUND: Over the last few decades, the annual global incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has steadily increased. Because of the complex and inconsistent treatment of GEP-NETs, the prognosis of patients with GEP-NETs is still difficult to assess. The study aimed to construct and validate the nomograms included treatment data for prediction overall survival (OS) in GEP-NETs patients. METHODS: GEP-NETs patients determined from the Surveillance, Epidemiology, and End Results (SEER)-13 registry database (1992-2018) and with additional treatment data from the SEER-18 registry database (1975-2016)...
January 19, 2024: International Journal of Surgery
https://read.qxmd.com/read/38238038/sequencing-of-somatostatin-receptor-based-therapies-in-neuroendocrine-tumor-patients
#17
JOURNAL ARTICLE
Jonathan R Strosberg, Taymeyah Al-Toubah, Ghassan El-Haddad, Diane Reidy Lagunes, Lisa Bodei
Most well-differentiated neuroendocrine tumors (NETs) express high levels of somatostatin receptors, particularly subtypes 2 and 5. Somatostatin analogs (SSAs) bind to somatostatin receptors and are used for palliation of hormonal syndromes and control of tumor growth. The long-acting SSAs octreotide long-acting release and lanreotide are commonly used in the first-line metastatic setting because of their tolerable side effect profile. Radiolabeled SSAs are used both for imaging and for treatment of NETs. 177 Lu-DOTATATE is a β-emitting radiolabeled SSA that has been proven to significantly improve progression-free survival among patients with progressive midgut NETs and is approved for treatment of metastatic gastroenteropancreatic NETs...
January 18, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38229586/spatial-profiling-reveals-tissue-specific-neuro-immune-interactions-in-gastroenteropancreatic-neuroendocrine-tumors
#18
JOURNAL ARTICLE
Suzann Duan, Travis W Sawyer, Brandon L Witten, Heyu Song, Tobias Else, Juanita L Merchant
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous malignancies that arise from complex cellular interactions within the tissue microenvironment. Here, we sought to decipher tumor-derived signals from the surrounding microenvironment by applying digital spatial profiling (DSP) to hormone-secreting and non-functional GEP-NETs. By combining this approach with in vitro studies of human-derived organoids, we demonstrated the convergence of cell autonomous immune and pro-inflammatory proteins that suggests their role in neuroendocrine differentiation and tumorigenesis...
January 17, 2024: Journal of Pathology
https://read.qxmd.com/read/38214130/establishing-a-robust-radioligand-therapy-program-a-practical-approach-for-north-american-centers
#19
REVIEW
Erik S Mittra, Rebecca K S Wong, Celeste Winters, Adam Brown, Shondra Murley, Hagen Kennecke
Radioligand therapy (RLT) is a targeted approach to treating cancer that has been shown to be safe and effective in a variety of disease states, including gastroenteropancreatic neuroendocrine tumors, lymphoma, and most recently, advanced prostate cancer. In the United States, patient access to this therapy is currently variable. Implementation of new RLT programs and expansion of existing programs are needed to broaden patient access to and standardize the delivery of RLT, especially as new therapies are introduced into clinical practice...
January 12, 2024: Cancer Medicine
https://read.qxmd.com/read/38206830/combined-lanreotide-autogel-and-temozolomide-treatment-of-progressive-pancreatic-and-intestinal-neuroendocrine-tumors-the-phase-ii-sonnet-study
#20
JOURNAL ARTICLE
Marianne Pavel, Harald Lahner, Dieter Hörsch, Anja Rinke, Timm Denecke, Arend Koch, Benjamin Regnault, Dorit Helbig, Philipp Hoffmanns, Markus Raderer
BACKGROUND: In advanced neuroendocrine tumors (NET), antiproliferative treatment options beyond somatostatin analogs remain limited. Temozolomide (TMZ) has shown efficacy in NET alone or combined with other drugs. MATERIALS AND METHODS: SONNET (NCT02231762) was an open, multicenter, prospective, phase II study to evaluate lanreotide autogel 120 mg (LAN) plus TMZ in patients with progressive advanced/metastatic grade 1/2 gastroenteropancreatic (GEP) NET or of unknown primary...
January 11, 2024: Oncologist
keyword
keyword
158416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.